Analysis of molecular markers as predictive factors of lymph node involvement in breast carcinoma

Abstract

Abstract. Nodal status is the most significant independent prognostic factor in breast cancer. Identification of molecular markers would allow stratification of patients who require surgical assessment of lymph nodes from the large numbers of patients for whom this surgical procedure is unnecessary, thus leading to a more accurate prognosis. However, up to now, the reported studies are preliminary and controversial, and although hundreds of markers have been assessed, few of them have been used in clinical practice for treatment or prognosis in breast cancer. The purpose of the present study was to determine whether protein phosphatase Mg2+/Mn2+ dependent 1D, β-1,3-N-acetylglucosaminyltransferase, neural precursor cell expressed, developmentally down-regulated 9, prohibitin, phosphoinositide-3-kinase regulatory subunit 5 (PIK3R5), phosphatidylinositol-5-phosphate 4-kinase type IIα, TRF1-interacting ankyrin-related ADP-ribose polymerase 2, BCL2 associated agonist of cell death, G2 and S-phase expressed 1 and PAX interacting protein 1 genes, described as prognostic markers in breast cancer in a previous microarray study, are also predictors of lymph node involvement in breast carcinoma Reverse transcription-quantitative polymerase chain reaction analysis was performed on primary breast tumor tissues from women with negative lymph node involvement (n=27) compared with primary tumor tissues from women with positive lymph node involvement (n=23), and was also performed on primary tumors and paired lymph node metastases (n=11). For all genes analyzed, only the PIK3R5 gene exhibited differential expression in samples of primary tumors with positive lymph node involvement compared with primary tumors with negative lymph node involvement (P= 0.0347). These results demonstrate that the PIK3R5 gene may be considered predictive of lymph node involvement in breast carcinoma. Although the other genes evaluated in the present study have been previously characterized to be involved with the development of distant metastases, they did not have predictive potential.

Management of the Axilla in the Era of Breast Cancer Heterogeneity

“…These results need to be confirmed in a prospective study with a large cohort. More recently, Paula et al tried to identify prognostic markers in patients with pN0 and pN + BC ( 45 ) and found that the PIK3R5 gene was differentially expressed in these two groups. However, they did not assess the correlation with the patients’ outcome.…”

Análise De Expressão Gênica Na Identificação De Potenciais Marcadores Preditivos Em Neoplasias Malignas Mamárias

“…Contudo, a maioria dos trabalhos de expressão gênica avalia somente o potencial prognóstico dos genes, enquanto uma quantidade reduzida analisa o poder preditivo de genes em amostras de neoplasias primárias e metástases de linfonodos em câncer de mama (BERTUCI et al, 2000;HUANG et al, 2003;ABBA et al, 2007;FENG et al, 2007;WANG et al, 2013;VALENTE et al, 2014;CHEN et al, 2017;PAULA et al, 2017). Além disso, o significado biológico do envolvimento dos linfonodos e sua utilidade na orientação da terapia adjuvante e sistêmica tem sido objeto de muitos resultados discordantes (BERTUCI et al, 2000;HUANG et al, 2003;ABBA et al, 2007).…”

“…Em relação à análise de expressão em genes individuais como potenciais fatores preditivos em tumores mamários, também há poucos estudos publicados na literatura (WANG et al, 2013;SHRIVER;HUEMAN;ELLSWORTH, 2014;PAULA et al, 2017;CHEN et al, 2017). Shriver, Hueman e Ellsworth (2014) detectaram a expressão diferencial dos genes DKK1, IGJ, SCGB1D2, SERPINA1, TFF1, TFF3 e TMSB15A quando compararam neoplasias malignas primárias obtidas de pacientes linfonodo negativo com neoplasias malignas primárias linfonodo positivo, sugerindo esses genes como potenciais marcadores preditivos em câncer de mama.…”

“…Em um estudo prévio de nosso grupo (PAULA et al, 2017), no qual se utilizaram as mesmas amostras e critérios de avaliação, que, no presente estudo, foi realizada a análise das características clinico-patológicas das pacientes, cujos resultados obtidos estão descritos na Tabela 2. A idade média das pacientes ao diagnóstico foi de 57 anos (53-60 anos).…”

A five‑gene based risk score with high prognostic value in colorectal cancer

“…Microarray technology allows comprehensive analysis of gene expression profiles in different diseases, which has been demonstrated in a variety of hematological tumors and solid tumors including lung ( 6 ), liver ( 7 ), pancreas ( 8 ), and breast ( 9 ). Biomarkers discovered by microarrays have a great potential in the prediction of clinical outcomes and survival as well as classification in different sub-types ( 10 – 12 ).…”